LimmaTech has pioneered vaccine development technologies to build a pipeline of vaccine programs to protect against and prevent severe infections caused by pathogens that have become resistant to antimicrobial treatments.
We leverage our decades of experience in vaccine technologies and development and our understanding of pathogens to tailor vaccine approaches with the potential to protect lives and reduce the threat of increasing microbial resistance.
At LimmaTech, we are convinced that access to highly efficient vaccines represents a vital and indispensable part of the strategy to fight antimicrobial resistance (AMR) by preventing infections before they take hold and averting disease manifestation. The time is now to efficiently address rapidly increasing AMR, one of the most pressing global public health concerns.
We are using our profound expertise in engineering E. coli to create complex carbohydrate and protein molecules that can deliver cutting-edge vaccine solutions against infectious diseases. Through our proprietary multivalent vaccine technology platform and other pathogen-specific vaccine approaches, our vision is to broadly deliver affordable vaccine-induced protection against increasingly untreatable microbial infections, actively decrease the escalating risk of antibiotic resistance and take significant steps toward controlling highly transmissible diseases.
Led by a team with decades of vaccine development and manufacturing experience and backed by leading investment funds, LimmaTech is rapidly expanding its pipeline to deliver innovative vaccines that combat the challenges of emerging infections and AMR and address major global medical needs.
Learn more about our team here.